Skip to main content

Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions

Abstract

The study regarding load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction is very interesting. But there are a few things we need to pay attention to.

The present Commentary refers to the recently published article by Connelly et al. [1] describing that empagliflozin contributes to improving cardiac function in experimental heart failure with reduced ejection fraction (HFrEF). EMPA-REG OUTCOME demonstrated that patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care [2]. The underlying mechanisms are also being explored. It has been shown that empagliflozin improves hemodynamics in a hypertensive heart failure rat model, associated with renal protection, attenuated cardiac fibrosis, and normalization of HF genes [3]. Glycaemic control with empagliflozin significantly ameliorated myocardial oxidative stress injury and cardiac fibrosis in diabetic mice [4]. The drug also improves primary hemodynamic parameters and attenuates the progression of atherosclerosis by reducing hyperlipidemia and hyperglycemia [5] and reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats [6]. Moreover, empagliflozin improves coronary microvascular function and contractile performance in prediabetic ob/ob−/− mice [7] and attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway [8]. We believe that it is important and necessary to analyze and report the potential underlying mechanism of empagliflozin for the benefit of heart failure, especially HFrEF, both load-dependent and load-independent effects. This study identified experimental HFrEF model through ligation of the left anterior descending coronary artery to induce myocardial infarction of the left ventricle to suggest that empagliflozin had major beneficial effects on the principal load-independent measures of systolic function, preload recruitable stroke work relationship and end systolic pressure volume relationship, indicating its salutary effects were, at least in part, due to actions beyond a direct effect of reduced preload and afterload [1]. But there are a few things we need to pay attention to. Firstly, this study established an experimental HFrEF model after myocardial infarction. Although this post myocardial infarction model develops structural hallmarks of HFrEF [9], there are many causes of HFrEF, a more ideal model of heart failure is warranted. In addition, following confirmation of infarct size with echocardiography 1-week post myocardial infarction, animals were then further randomized to receive the vehicle, or the sodium-glucose linked cotransporter-2 inhibitor, empagliflozin (20 mg/kg/day by gavage), for 6 weeks [1]. Prior to randomized administration, the authors applied echocardiography only to determine the infarct size but did not confirm the structure of the heart, ejection fraction value, and other typical features and phenotypes of HFrEF. Thirdly, 20 mg/kg/day of empagliflozin was administrated, this is really too much. Remember, the dose of empagliflozin is only 10 mg or 25 mg once daily in clinical trials [2, 10], translating less than 3 mg/kg/day for rats. Finally, this is an experimental study, that is to say, a report from nonhuman study. We need evidence from clinical trials to further confirm this.

Availability of data and materials

Not applicable.

Abbreviations

HFrEF:

Heart failure with reduced ejection fraction

References

  1. Connelly KA, Zhang Y, Desjardins J-F, Nghiem L, Visram A, Batchu SN, Yerra VG, Kabir G, Thai K, Advani A, et al. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19(1):13.

    Article  Google Scholar 

  2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  Google Scholar 

  3. Lee H-C, Shiou Y-L, Jhuo S-J, Chang C-Y, Liu P-L, Jhuang W-J, Dai Z-K, Chen W-Y, Chen Y-F, Lee A-S. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45.

    Article  Google Scholar 

  4. Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.

    Article  Google Scholar 

  5. Dimitriadis GK, Nasiri-Ansari N, Agrogiannis G, Kostakis ID, Randeva MS, Nikiteas N, Patel VH, Kaltsas G, Papavassiliou AG, Randeva HS, et al. Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Mol Cell Endocrinol. 2019;494:110487.

    Article  CAS  Google Scholar 

  6. Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, García-Caballero T, Rodríguez-Segade S, Rodríguez J, et al. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019;170:113677.

    Article  Google Scholar 

  7. Adingupu DD, Göpel SO, Grönros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, Gan L-M, Jönsson-Rylander A-C. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice. Cardiovasc Diabetol. 2019;18(1):16.

    Article  Google Scholar 

  8. Lu Q, Liu J, Li X, Sun X, Zhang J, Ren D, Tong N, Li J. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway. Mol Cell Endocrinol. 2020;501:110642.

    Article  Google Scholar 

  9. van Heerebeek L, Borbély A, Niessen HWM, Bronzwaer JGF, van der Velden J, Stienen GJM, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113(16):1966–73.

    Article  Google Scholar 

  10. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41(2):356–63.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all scientists and participants involved in HFrEF. We would like to extend our highest thanks and respect to public health professionals and medical professionals combating COVID-19!

Funding

This work was funded by National Natural Science Foundation of China (81774229), Jiangsu Leading Talent Project of Traditional Chinese Medicine (Jiangsu TCM 2018 No. 4), Jiangsu Science and Technology Department Project (BK20161115), Major Project of Nanjing Medical Science and Technology Development during 13th Five-year Plan (ZDX16013), and Jiangsu Universities Nursing Advantage Discipline Project (2019YSHL095).

Author information

Authors and Affiliations

Authors

Contributions

BL, YXZ and NG analyzed and interpreted the data. BL was a major contributor in writing the manuscript. NG contributed to critical revision of the manuscript. All authors contributed to data acquisition, data analysis, or data interpretation. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ning Gu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, B., Zhao, YX. & Gu, N. Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions. Cardiovasc Diabetol 19, 29 (2020). https://doi.org/10.1186/s12933-020-01004-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12933-020-01004-9

Keywords